AI assistant
BridgeBio Pharma, Inc. — Director's Dealing 2024
Jul 30, 2024
30604_dirs_2024-07-29_e3a30c6d-0bac-4d6e-8345-c7e117fdf6bf.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 3 — Initial Statement of Beneficial Ownership
Issuer: BridgeBio Pharma, Inc. (BBIO)
CIK: 0001743881
Period of Report: 2024-07-23
Reporting Person: Trimarchi Thomas (N/A)
Holdings (Non-Derivative)
| Security | Shares | Ownership |
|---|---|---|
| Common Stock | 394856 | Direct |
Holdings (Derivative)
| Security | Exercise Price | Expiration | Underlying | Shares | Ownership |
|---|---|---|---|---|---|
| Stock Option (Right to Buy) | $17 | 2029-06-25 | Common Stock (115000) | Direct | |
| Stock Option (Right to Buy) | $42.19 | 2030-09-17 | Common Stock (16419) | Direct | |
| Stock Option (Right to Buy) | $68.87 | 2031-02-09 | Common Stock (22145) | Direct | |
| Stock Option (Right to Buy) | $40.03 | 2031-12-01 | Common Stock (158127) | Direct |
Footnotes
F1: The stock option is fully vested and exercisable. The stock option vested in 48 monthly installments from June 26, 2019 to June 26, 2023.
F2: The stock option is fully vested and exercisable. The stock option vested as to 2,736 shares on October 18, 2020 and as to the remainder of the shares in 40 monthly installments thereafter through February 18, 2024.
F3: 18,915 of the shares subject to this option are vested and exercisable. The option vests in 48 equal monthly installments from February 10, 2021 to February 10, 2025, subject to the Reporting Person's continued service to the Issuer through each such date.
F4: 102,123 of the shares subject to this option are vested and exercisable. The option vested as to 25% of the shares on December 2, 2022 and as to the remainder of the shares in 36 monthly installments thereafter through December 2, 2025, subject to the Reporting Person's continued service to the Issuer through each such date.